Stemline Therapeutics, Inc. (STML) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Stemline Therapeutics, Inc. (NASDAQ:STML) in a research report report published on Tuesday morning. They currently have a $34.00 target price on the biopharmaceutical company’s stock.
A number of other equities research analysts have also weighed in on STML. Zacks Investment Research raised Stemline Therapeutics from a sell rating to a hold rating in a research report on Saturday, May 20th. Jefferies Group LLC reaffirmed a buy rating and set a $16.00 target price on shares of Stemline Therapeutics in a research report on Thursday, May 25th. ValuEngine lowered Stemline Therapeutics from a hold rating to a sell rating in a research report on Wednesday, May 31st. Cowen and Company reaffirmed a buy rating on shares of Stemline Therapeutics in a research report on Wednesday, June 14th. Finally, BidaskClub raised Stemline Therapeutics from a hold rating to a buy rating in a research report on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $29.17.
Stemline Therapeutics (STML) opened at 9.95 on Tuesday. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60. The stock’s market capitalization is $233.38 million. The stock’s 50 day moving average price is $8.73 and its 200 day moving average price is $8.62.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.18). The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative net margin of 4,176.84% and a negative return on equity of 67.35%. On average, equities research analysts predict that Stemline Therapeutics will post ($2.56) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/13/stemline-therapeutics-inc-stml-receives-buy-rating-from-hc-wainwright.html.
Several large investors have recently made changes to their positions in STML. Nationwide Fund Advisors increased its holdings in shares of Stemline Therapeutics by 7.8% in the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 858 shares during the period. Voya Investment Management LLC purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $102,000. Wells Fargo & Company MN increased its holdings in shares of Stemline Therapeutics by 3.8% in the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stemline Therapeutics in the 1st quarter valued at $120,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $147,000. Institutional investors and hedge funds own 48.42% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.